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The overlap between Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis is a 
neglected area of research and there are no guidelines for clinical practice.  We provide a position 
statement from the BRONCH-UK consortium, intended to be of interest to both the clinician and 
researcher.  Whilst making recommendations based on expert consensus, one of our aims is to 
provoke debate.  Through discussion of this overlap we also aim to promote research in the area, 
driving improvements in patient care. 
 
1.  Definitions and Diagnosis: why an overlap syndrome and/or co-diagnosis exists 
COPD and bronchiectasis share common symptoms of cough with sputum production and 
susceptibility to recurrent exacerbations driven by new or persistent infection.  Patients presenting 
de novo may therefore present a diagnostic challenge. 
COPD is diagnosed on the basis of poorly reversible airflow obstruction, and is therefore a 
physiological diagnosis.  It is defined [1] when an objective measure of airflow obstruction is 
associated with an abnormal inflammatory response of the lung to noxious stimuli, with cigarette 
smoke the most common exposure in the developed world.  Operationally this implies that patients 
with any sufficient exposure and fixed airflow obstruction are labelled as having COPD. 
Bronchiectasis is diagnosed in the presence of airway dilatation and airway wall thickening on 
imaging (usually computed tomography, CT) and is therefore a structural diagnosis.  Clinically 
significant disease is present when imaging abnormalities are associated with symptoms of 
persistent or recurrent bronchial infection [2].  An increasing number of patients with COPD have a 
CT scan as part of their diagnosis and follow-up care, with consequent impact on detection of airway 
wall changes.  Airway wall changes in COPD are typically mild and diffuse, whereas those in 
bronchiectasis may be localised or diffuse depending on the aetiology, and mild or more severe 
including varicose and/or cystic change (Figure 1). 
Physiologic criteria for the diagnosis of COPD, and structural criteria for the diagnosis of 
bronchiectasis create the possibility for individual patients to fulfil both, resulting conceptually in 
either co-diagnosis or an overlap syndrome between the two conditions.  The prevalence of this 
overlap will vary depending on the respective prevalence of COPD and bronchiectasis in the 
population under consideration. 
 
FIGURE 1: Typical airway wall changes in COPD (left) are diffuse, and may be associated with co-
existent emphysema.  Airway wall changes in primary bronchiectasis (right) may be localised or 
diffuse, and may be more severe resulting in cystic and/or varicose appearances.   
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2.  Why the overlap between COPD and Bronchiectasis is important. 
What is the relevance for patients who fulfil both diagnoses?  Establishing the primary diagnosis is 
important as it has implications for optimal diagnosis and treatment. 
Firstly, the range of necessary aetiological investigations differs with resultant resource implication.  
For example, the low pick up rate for alpha-1 antitrypsin deficiency in bronchiectasis means that 
testing is not recommended in the aetiological work up for bronchiectasis [2].  In contrast, the GOLD 
document recommends such testing in early onset and/or severe COPD.  Assessment of serum 
immunoglobulins is mandatory in the assessment of bronchiectasis, but does not currently form part 
of COPD guidelines, even in patients experiencing recurrent exacerbations.  Establishing a primary 
diagnosis of  COPD with secondary changes of bronchiectasis versus primary bronchiectasis with 
secondary fixed-airflow obstruction  can be challenging.  In patients who have smoked, a preceding 
long history of dyspnoea without infective symptoms, the presence of emphysema, and mild, diffuse 
bronchiectasis all suggest that COPD is the primary problem.  A smoking history less than 20pack 
years makes COPD less likely and, anecdotally, many patients with primary bronchiectasis have 
never smoked. 
Secondly, treatments useful in COPD may not be widely effective in bronchiectasis and vice versa. 
Inhaled corticosteroids provide perhaps the best example of this, widely used in COPD and not 
recommended for most patients with bronchiectasis [2].  The reasons for this are unclear, but likely 
reflect, in part, the diverse aetiology underlying bronchiectasis.  In contrast, inhaled antibiotics, 
including anti-Pseudomonal agents in appropriate patients [3], are  of benefit [4] and appear in 
current bronchiectasis guidelines [2] but are not used routinely in stable COPD.  Bronchiectasis 
guidelines [2] suggest 14 days of antibiotics for treating bronchiectasis exacerbations but courses in 
COPD should be considerably shorter.  Extrapolating this to COPD-associated bronchiectasis could 
greatly increase the use of antibiotics at a time when antimicrobial resistance is a major concern.  
However, as noted below, this group of patients have a poorer prognosis and therefore there 
remains the need to identify which regimes are most effective. 
 
3. The importance of anatomic bronchiectasis in COPD. 
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The prevalence of airway wall thickening and dilatation that would fulfil the definition of 
bronchiectasis increases with increasing spirometric severity of COPD.  A key UK study [5] found that 
30% of a primary care COPD population had airway wall abnormalities potentially classifiable as 
bronchiectatic.  There is currently much interest in identifying specific ‘phenotypes’ of COPD: groups 
of patients with specific characteristics who may respond to a particular therapy, or experience a 
particular prognosis.  Phenotypes may co-exist and it is likely that there is an overlap between 
airway wall thickening and dilatation on CT suggesting bronchiectasis and the chronic bronchitis 
phenotype.  It is important to recognise that standardisation in reporting of airway wall thickening 
and dilatation is challenging, and may be different across studies with the resultant risk of over-
diagnosis.  At present, COPD is not considered a cause of bronchiectasis.  However, whilst significant 
studies with longitudinal data are lacking, the high prevalence of airway wall abnormalities in COPD 
challenges this assumption.  A recent study of 201 COPD patients with airway wall abnormalities 
typical of bronchiectasis confirmed an association with exacerbations, and was predictive of 
mortality over 48 months [6].  A further, single centre study demonstrated a near three-fold 
increased mortality rate, with patients with bronchiectasis and associated COPD having a five year 
mortality of 55% compared to 20% in those with bronchiectasis without COPD [7].  In comparison, 
the landmark TORCH Trial in COPD had a 3 year mortality rate of less than 20% [8].  With the 
increasing clinical use of CT in patients with COPD (assessment for volume reduction, screening for 
lung cancer, coronary artery calcification assessment and investigation of nodules and haemoptysis, 
for example), the presence of “bronchiectatic” airway wall changes is increasingly documented and 
the implications of this need to be established. 
 
4. The importance of fixed airflow obstruction in bronchiectasis. 
When examining collections of patients known to clinicians in secondary care, a proportion of 
patients will exhibit fixed airflow obstruction, and therefore meet the spirometric diagnostic criteria 
for COPD.  However, the prevalence of fixed airflow obstruction in bronchiectasis varies by the 
population of bronchiectasis patients studied, a problem common to much bronchiectasis research.  
Airflow obstruction is perhaps best considered one marker of disease severity in bronchiectasis.  
Known for some time, this has more recently been operationalised with the development of two 
prognostic scores – BSI [9] and FACED [10] – both of which include FEV1 as a component in the 
prognostic models [11] (though FEV1 may also be reduced in the context of restrictive disease).  
There is clearly real need to develop new therapies to address the small airway disease common to 
both conditions that is the most important site of airflow obstruction. 
 
5. Recommendations / Summary. 
In summary, COPD and bronchiectasis may co-exist as an overlap syndrome.  Two studies suggest 
the overlap is associated with increased mortality. 
We make the following recommendations: 
1.  It is important to assess whether COPD or bronchiectasis is the primary diagnosis, to guide 
investigative strategy and treatment (Table 1).  In those patients where this is not possible, 
investigating both conditions may be necessary. 
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2.  In patients with primary bronchiectasis, fixed airflow obstruction is best considered one marker of 
disease severity, identifying patients with a poorer prognosis.  The mechanisms, risk factors and 
potential management options for these patients are largely unknown demanding more research. 
3.  The anatomic airway abnormalities of bronchiectasis in patients with primary COPD are best 
considered a phenotype of the COPD disease spectrum.  Further work is needed to define the 
pathogenesis and clinical consequences of this phenotype, particularly in terms of prognosis and 
whether the presence of anatomical bronchiectasis should alter the therapeutic approach. 
4.  For patients with both diagnoses, who therefore have a true overlap syndrome, there is the need 
to understand more about the condition with specific regard to epidemiology, natural history, and 
treatment. 
 
TABLE 1: Is COPD or bronchiectasis the primary diagnosis? 
 
 COPD Bronchiectasis 
History of Respiratory 
Exposure, typically to Tobacco 
smoke 
Necessary* Not necessary 
Fixed Airflow Obstruction Necessary Not necessary 
Airway Wall Abnormality at CT Not necessary Necessary 
*: except Alpha-1 antitrypsin deficiency 
 
BRONCH-UK is funded by the UK Medical Research Council to foster collaborative research in (non-
cystic fibrosis) bronchiectasis. 
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